"Incredibly promising" results for Enhertu in breast cancer presented at ESMO

UK pharma major AstraZeneca (LSE: AZN) says a new Phase III clinical trial of Enhertu (trastuzumab deruxtecan) has demonstrated a 72% reduction in the risk of disease progression or death in women with HER2-positive metastatic breast cancer compared to a different medicine.

The findings prompted Citi to reiterate its “buy” recommendation for AstraZeneca, forecasting global revenues of $10 billion in 2030 for Enhertu.

The results of the DESTINY-Breast03 trial were presented in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2021. They were described as “incredibly promising results” by Dr Kotryna Temcinaite, senior communications manager at Breast Cancer Now, who said: “It is fantastic to see that Enhertu could give hundreds of people with HER2 positive incurable secondary breast cancer the chance of more time before their disease progresses.”